BioCryst to Present New ORLADEYO® (berotralstat) Data at 2022 American Academy of Allergy, Asthma & Immunology Annual Meeting
RESEARCH TRIANGLE PARK, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX)…
News
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022
ImmixBio Management Answers Top-Voted Investor Questions at IMMX Investors Day February 1, 2022 Immix Biopharma,…
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302
Innovator Behind Pancreatic Cancer-Focused Program Becomes Scientific Advisor CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE)…
Clover Appoints Nicholas Jackson, Ph.D., as President of Global Research and Development
CHENGDU, China, Feb. 01, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a…
Denali Therapeutics Announces Presentations on DNL310 (ETV:IDS) Development Program in MPS II (Hunter Syndrome) at the Upcoming WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI),…
Sorrento Completes Acquisition of Virex Health, Will Commercialize Next-Generation at-Home Diagnostic Testing That Rivals PCR-Level Sensitivity for Daily Covid-19 Tests and Early Cancer Diagnosis
Virex Health, Inc. is a Boston, Massachusetts company that has developed a powerful, broadly applicable…
Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT
WOBURN, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a…
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) — Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical…
Quotient Limited Provides MosaiQ Regulatory & Commercial Update
The company remains in contact with the European Notified Body and continues to anticipate approval…
POINT Biopharma Provides Update on Manufacturing, Supply Chain and Late-Stage Programs
Company’s radiopharmaceutical manufacturing facility now operational, supplying doses for the Phase 3 SPLASH trial –…
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer
Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path…
Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
— Phase 3 ENABLAR-2 Clinical Trial for 2nd Line Treatment of AR+ER+HER2- Metastatic Breast Cancer Expected…
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
SAN DIEGO, CA, Feb. 01, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye”…
Rubius Therapeutics to Present at the Virtual Guggenheim Healthcare Talks and SVB Leerink Global Healthcare Conference in February 2022
CAMBRIDGE, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage…
Arcutis Completes Enrollment of STRATUM Pivotal Phase 3 Trial of Topical Roflumilast Foam in Individuals with Seborrheic Dermatitis
Topline data now anticipated in mid-year 2022, followed by a regulatory submission in first half…
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome
Data anticipated in first quarter 2022 WARRINGTON, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) — Windtree…
Mydecine Submits Pre-Investigational New Drug Briefing Package to the FDA for MYCO-001 Seamless Phase 2/3 Smoking Cessation Clinical Trial
DENVER, Feb. 01, 2022 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE:…
Aleafia Health Provides Further Update on its Convertible Debt
Entered into Forbearance Agreement with Holders representing 58% of total Debentures Negotiating a potential transaction…
Biogen Exercises Option to Participate in the Development and Commercialization of a Late-Stage Bispecific Antibody
Mosunetuzumab is an investigational T-cell engaging bispecific antibody targeting CD20 and CD3 in development for…
Syneos Health Schedules Fourth Quarter and Full Year 2021 Earnings Call for Thursday, February 17th, 2022
MORRISVILLE, N.C., Feb. 01, 2022 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated…